Medical Drugs News
-
Showcase
ARAI-2PAM Barda Procurement Award
Broomfield, Colorado, 10/3/2022. Aktiv Pharma Group (Aktiv) today announced a procurement contract award from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Under this contract (number 75A50122C00082), awarded under the 2004 Project ...
-
Showcase
FDA Emerging Technology Program
Broomfield Colorado 6/16/2022. Aktiv Pharma Group (Aktiv) announced today the acceptance of its novel glass-free, film-based flexible primary drug container (PDC) technology for sterile injectables named ARCH, into the US Food and Drug Administration (FDA) Emerging Technology Program (ETP). The ETP is a collaborative effort which supports the FDA’s mission to facilitate modernization in ...
-
Showcase
Aktiv Pharma Group Receives Grant Funding to Develop Tranexamic Acid Autoinjector
Broomfield Colorado 6/25/2022. Aktiv Pharma Group (Aktiv) announced today a grant award from the U.S. Department of Defense (DOD) Defense Health Agency (DHA) Joint Program Committee 6/Combat Casualty Care Research Program (JPC-6/CCCRP) [1] for the continued development of a tranexamic acid (TXA) autoinjector, targeting proposed indications related to prehospital treatment of severe bleeding. ...
-
Showcase
POP Biotechnologies Vaccine Technology to Enter Phase III Clinical Studies as part of Eubiologics’ COVID-19 Vaccine Candidate, EuCorVac-19
POP Biotechnologies (POP BIO), a Buffalo, NY based biopharmaceutical startup, announces the approval of the plan for a phase 3 clinical study of EuCorVac-19, a COVID-19 vaccine candidate developed by South Korean partner EuBiologics (KOSDAQ: 206650, CEO, Dr. Baik YoungOk, Mr. Seukkeun Choi) from the Ministry of Food and Drug Safety in South Korea. EuCorVac-19, is a protein-based vaccine ...
-
Showcase
Onapristone Extended Release: Safety Evaluation from Phase I–II Studies with an Emphasis on Hepatotoxicity
Introduction Anliprogestins have demonstrated promising activity against breast and gynecological cancers, but liver-related safety concerns limited the advancement of this therapeutic class. Onapristone is a full progesterone receptor antagonist originally developed as an oral contraceptive and later evaluated in phase II studies for metastatic breast cancer. Because of liver enzyme elevations ...
-
Showcase
Empatica and BARDA Join Forces to Validate Wearable System That Detects COVID-19 Before Symptoms Appear
BOSTON, June 19, 2020 /PRNewswire/ -- Digital healthcare company Empatica announces a pioneering new partnership with the Biomedical Advanced Research and Development Authority ("BARDA"), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS), to validate an early warning system for COVID-19 and other respiratory ...
-
Showcase
ALung Announces Commercial Development of its Breakthrough Next Generation Artificial Lung
PITTSBURGH–(BUSINESS WIRE)– April 4, 2020 – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced the recent initiation of commercial development of its next generation artificial lung, which expands the Company’s focus on highly efficient gas ...
-
Showcase
Zeneo® Midazolam Earns The Orphan Drug Designation
The American Food and Drug Administration (FDA) has granted Orphan Drug Designation to ZENEO® Midazolam for the treatment of status epilepticus (epileptic seizure lasting longer than 5 minutes). The orphan designation for ZENEO® Midazolam improves Crossject’s international visibility and gives impetus to its current negotiations for partnerships with pharmaceutical laboratories. ...
By Crossject
-
Matexcel Provides Expansive Array of Bio-ink Products for Different Applications
Matexcel, a leading innovator in advanced materials and bioengineering, today announced its diverse portfolio of bio-ink products, empowering researchers across various fields to unlock the potential of 3D bioprinting. This comprehensive range, featuring tailored bio-inks for specific applications, paves the way for revolutionary advancements in regenerative medicine, drug discovery, and beyond. ...
By Matexcel
-
CD Formulation Extends Holiday Greetings for 2023 with an Exclusive Discount
CD Formulation, a leading provider of bioformulation and analytical services, is spreading holiday cheer in 2023 with an exciting offer for its valued customers. The company is extending a generous discount on its range of innovative products and services, allowing customers to make the most of their holiday budget. Being at the forefront of the biotechnology industry, CD Formulation provides ...
-
Stability Analysis Plays a Crucial Role in Pharmaceutical Formulation, Highlighted by CD Formulation
In the field of pharmaceutical formulation, stability analysis is a critical aspect that ensures the safety and efficacy of drugs throughout their shelf life. CD formulation has introduced a series of stability analysis services as a prominent tool for researchers to understand the influence of various factors and tests on the stability of pharmaceutical products. With extensive expertise in ...
-
Alfa Chemistry Leads the Way to Unleash Power of Computational Solutions in Solid State Chemistry for Pharmaceutical Research
In the ever-evolving field of pharmaceutical research, the hunt for effective drugs often rests on the ability to understand and manipulate the solid-state properties of compounds. Alfa Chemistry, a leading provider of research and development solutions, is taking the lead in harnessing the power of computational solutions in solid state chemistry to facilitate pharmaceutical research. ...
-
BOC Sciences and Spaya Join Forces to Expand Chemical Offerings
BOC Sciences, a leading chemical supplier, has partnered with Spaya, an AI-powered chemical synthesis platform, to enhance the portfolio of commercially available materials by listing an unprecedented 140,000+ chemical products. BOC Sciences supplies a diverse array of research chemicals and biochemicals while Spaya's groundbreaking technology simplifies the search and procurement process for ...
By BOC Sciences
-
Impel Pharmaceuticals Announces Filing of Voluntary Chapter 11 Cases and Signing of `Stalking Horse` Agreement to Facilitate Sale
Patient Access to Trudhesa® to Continue Uninterrupted Sufficient Liquidity to Fund Day to Day Operations During Court-Supervised Process Impel Pharmaceuticals Inc. (OTCQX: IMPL) ("Impel" or "the Company"), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced that ...
-
Cell Metric X Captures Distinguished Nomination for ‘Best New Drug Discovery & Development Product’ In Scientists’ Choice Awards
Laboratory scientists across the world are being invited to have their say in the 2024 Scientists’ Choice Awards®. The annual Scientists’ Choice Awards celebrate the most innovative and effective technologies of the past year and provide scientists worldwide with the opportunity to acknowledge the instruments, assays, tools, or consumables that have made the most difference to ...
-
Almirall and etherna enter into a multi-target alliance to develop mRNA-based therapies in medical dermatology
The multi-target research and development partnership will focus on severe skin diseases The collaboration leverages etherna’s proprietary mRNA and lipid nanoparticle (LNP) technology with Almirall’s expertise in the dermatology space In addition to upfront and technology access payments, etherna is eligible to receive €300 million in development and commercial ...
By eTheRNA
-
PDA Announces the Jette Christensen Early Career Professional Grant in Memory of Past PDA Chair
PDA today announced the establishment of the Jette Christensen Early Career Professional Grant in memory of the Immediate-Past Chair of the PDA Board of Directors, who passed away on October 24 after a long battle with cancer. As a PDA member, Board Member, and PDA Chair, Jette’s dedication to PDA’s mission of advancing pharmaceutical/biopharmaceutical manufacturing science and ...
-
Caresyntax Announces Strategic Collaboration with AAICO to Expand AI-based Solutions In Healthcare
Caresyntax has entered into a strategic collaboration with The Applied AI Company (AAICO), a leading AI technology company, to distribute novel software and artificial intelligence solutions throughout the UAE, US, and Europe. With this strategic engagement, the companies will combine their healthcare datasets and delivery resources to offer bundled software and services solutions to healthcare ...
By Caresyntax
-
Vitalograph celebrates 60th anniversary
Founded in 1963, in Maids Moreton, Vitalograph’s mission has remained unwavering over the past six decades – to improve the lives of people living with lung conditions through the development and manufacture of respiratory diagnostic solutions. As experts in pulmonary function, they also provide clinical drug trial services that enable the development of life-changing respiratory ...
-
Stefan Blomsterberg appointed as new CEO of Cellink Bioprinting AB
Stefan Blomsterberg has been appointed as the new CEO of CELLINK. Cecilia Edebo, current CEO, requested earlier this year to resign from her position to pursue a new career opportunity outside the BICO Group. At the time of her resignation, a recruitment process was initiated which concluded in the appointment of Stefan Blomsterberg. Stefan Blomsterberg (born 1964) brings 20+ years of experience ...
By CELLINK
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you